Search results
Results from the WOW.Com Content Network
Tumor markers may be used for the following purposes: Monitoring the malignancy; When a malignant tumor is found by the presence of a tumor marker, the level of marker found in the body can be monitored to determine the state of the tumor and how it responds to treatment. If the quantity stays the same during treatment it can indicate that the ...
Levels or presence of biomarker should readily distinguish between normal, cancerous, and precancerous tissue; Effective treatment of the cancer should change the level of the biomarker; Level of the biomarker should not change spontaneously or in response to other factors not related to the successful treatment of the cancer
G (1–4): the grade of the cancer cells (i.e. they are "low grade" if they appear similar to normal cells, and "high grade" if they appear poorly differentiated) S (0–3): elevation of serum tumor markers; R (0–2): the completeness of the operation (resection-boundaries free of cancer cells or not) Pn (0–1): invasion into adjunct nerves
Biomarkers found in blood, urine, or body tissues that can be introduced or elevated by the presence of one or more types of cancer. Pages in category "Tumor markers" The following 45 pages are in this category, out of 45 total.
Grading in cancer is distinguished from staging, which is a measure of the extent to which the cancer has spread. Pathology grading systems classify the microscopic cell appearance abnormality and deviations in their rate of growth with the goal of predicting developments at tissue level (see also the 4 major histological changes in dysplasia).
Tumor antigen is an antigenic substance produced in tumor cells, i.e., it triggers an immune response in the host. Tumor antigens are useful tumor markers in identifying tumor cells with diagnostic tests and are potential candidates for use in cancer therapy. The field of cancer immunology studies such topics.
Cancer staging can be divided into a clinical stage and a pathologic stage. In the TNM (Tumor, Node, Metastasis) system, clinical stage and pathologic stage are denoted by a small "c" or "p" before the stage (e.g., cT3N1M0 or pT2N0). This staging system is used for most forms of cancer, except brain tumors and hematological malignancies.
Because surrogate end-points allow researchers to assess a marker rather than the patient, it allows participants to act as their own control, and in many cases allows for easier blinding. In addition to surrogate endpoints , imaging biomarkers can be used as predictive classifiers , to assist in selecting appropriate candidates for particular ...